The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

Myelofibrosis (MF) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment (COMFORT-I,) a double-blind trial, where patients with interme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael, Miller, Carole, Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Sun, William, Sandor, Victor, Kantarjian, Hagop M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4055021/
https://ncbi.nlm.nih.gov/pubmed/23480528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12274
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados